Skye Bioscience's Investigational Drug Disappoints As Monotherapy For Weight Loss - Skye Bioscience (NASDAQ:SKYE)

Skye Bioscience's Investigational Drug Disappoints As Monotherapy For Weight Loss - Skye Bioscience (NASDAQ:SKYE)

Skye Bioscience Inc. (NASDAQ:SKYE) stock sank on Monday after the company released topline data from its 26-week Phase 2a CBeyond proof-of-concept study of nimacimab. The nimacimab monotherapy arm did not achieve the primary endpoint of weight loss compared to placebo (-1.52% vs. -0.26 for placebo, mITT). Preliminary pharmacokinetic analysis showed lower than expected drug exposure of nimacimab, supporting evaluation of higher dosing. Also Read:…

Skye plummets 60% on mid-stage data for nimacimab for weight loss

Skye Biosciences' nimacimab missed weight loss targets in phase 2a, but showed promise when given with Novo Nordisk's Wegovy. Read more here.

Skye’s obesity drug fails in mid-stage study

The drug, nimacimab, did not outperform placebo on its own, but the company said that it appeared to boost weight loss when used with Wegovy.

Skye Bioscience Reports Topline CBeyond™ Phase 2a Data from Nimacimab Monotherapy and Combination Clinical Trial

Nimacimab monotherapy did not meet its primary endpoint for weight loss; preliminary pharmacokinetic analysis showed lower than expected drug exposure,...

Skye’s cannabinoid drug fails in mid-stage obesity trial

Skye Bioscience’s obesity shot has failed in a mid-stage trial, adding to the evidence that cannabinoid receptor 1 inhibitors have little effect in the disease. Nimacimab, as Skye’s antibody is known, did not improve weight ...

Skye Bioscience’s obesity drug fails to meet main goal of mid-stage study - Regional Media News

(Reuters) -Skye Bioscience said on Monday its experimental drug did not help overweight adults achieve significant weight loss compared to placebo, failing to meet the main goal of a mid-stage study and sending its shares slumping 66% before the bell. The company said patients receiving the experimental drug, nimacimab, lost 1.52% of their body weight compared to 0.26% for those on placebo. However, patients who took nimacimab together with sema…